EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

HER2-Low Breast Cancer: Now and in the Future

Sora Kang, Sung-Bae Kim

Cancer Research and Treatment · 15.07.2024 · 56 (3) · 700-720

DOI: 10.4143/crt.2023.1138 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Research and Treatment, erschienen am 15.07.2024. Verfasst von Sora Kang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemato-oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is a heterogeneous disease, and its subtypes are characterized by hormone receptor and human epidermal growth factor receptor 2 (HER2) expression status. “HER2-low” tumors, which exhibit a low level of HER2 expression (immunohistochemistry 1+ or 2+ without gene amplification), were conventionally considered not amenable to anti-HER2 targeting agents based on the results of a phase III trial of trastuzumab. However, this perspective is being challenged by the emergence of novel anti-HER2 antibody-drug conjugates, such as trastuzumab-deruxtecan. These innovative therapies have demonstrated remarkable efficacy against HER2-low breast cancer, shedding new light on a previously overlooked category of breast cancer. Such promising results highlight the need for in-depth investigations of the biology and prognostic implications of HER2-low tumors. In this review, we comprehensively summarize the current evidence surrounding this topic and highlight areas that warrant further exploration and research in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansAntineoplastic Agents, ImmunologicalBiomarkers, TumorCamptothecinImmunoconjugatesMolecular Targeted TherapyPrognosisTrastuzumab

Stichwörter der Autor:innen

Breast neoplasmsDS-8201aHER2-low

Substanzen

Antineoplastic Agents, ImmunologicalBiomarkers, TumorCamptothecinImmunoconjugatesErb-b2 Receptor Tyrosine KinasesTrastuzumabERBB2 protein, humantrastuzumab deruxtecan

Autor:innen und Institutionen

  • Division of Hemato-oncology, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Zitieren

APA

Kang, S., & Kim, S. B. (2024). HER2-Low Breast Cancer: Now and in the Future. Cancer Research and Treatment, 56(3), 700-720. https://doi.org/10.4143/crt.2023.1138

Vancouver

Kang S, Kim SB. HER2-Low Breast Cancer: Now and in the Future. Cancer Research and Treatment. 2024;56(3):700-720. doi:10.4143/crt.2023.1138

BibTeX
@article{Kang2024,
  author = {Kang, Sora and Kim, Sung-Bae},
  title = {HER2-Low Breast Cancer: Now and in the Future},
  journal = {Cancer Research and Treatment},
  year = {2024},
  volume = {56},
  number = {3},
  pages = {700--720},
  doi = {10.4143/crt.2023.1138}
}
Kostenlos starten →